Success Stories: EB-1A Approved in 2 Months 10 Days for A Scientist II from India With the Help of Premium Processing
Client’s Testimonial:
“Thank you for your great help and service, we are now one inch closer to our dream, thank you!”
On October 21st, 2020, we received another EB-1A (Alien of Extraordinary Ability) approval for a Scientist II in the Field of Pharmacology (Approval Notice).
General Field: Pharmacology
Position at the Time of Case Filing: Scientist II
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: October 21st, 2020
Processing Time: 2 months 10 days (Premium Processing Requested)
Case Summary:
A scientist II from India, holding a Ph.D. in pharmaceutics chose us to compose an EB-1A (Alien of Extraordinary Ability) petition. He knew that we would walk miles to lead him to EB1A victory. Thus, we began to assess his provided testimonies and established his extensive experience in pharmacokinetic and pharmacodynamic principles, drug development, and clinical study design, among other areas, thereby confirming his extraordinary ability to persevere with his research work in the U.S. Finally, we counter-signed the attorney-client agreement and prepared our client’s case to be submitted to the USCIS.
Our client’s EB-1A petition packet contained:
1. We detailed his research work on pharmacokinetics and drug dosing and how it addresses some of our nation’s and the world’s most pressing issues, including treating serious diseases such as blood cancers and fungal infections and establishing drug dosing recommendations for children.
2. Also, we recorded the 9 peer-reviewed scientific articles published by him in some of the most distinguishing journals in the field. These highly selective journals have consistently accepted his research for publication, noting that our client’s work is considered to be among the best in the field. We observed further that he not only conducted important original research but also judged the work of others 34 times.
3. Additionally, we detailed the citation record of his publication i.e. (94 citations, at the time of filing). He completed and published the results of his research in the field, and his work has been cited by researchers in at least 22 countries, demonstrating that these publications are greatly relied upon in the field of pharmacology.
4. We added six recommendation letters in our EB1A petition packet in support of his petition further. The letters were acquired from fellow experts in the field, elaborating on our client’s substantial role in advancing pharmacology. According to one of the recommenders:
“It is frankly necessary for researchers of [client’s] caliber to be accepted into the U.S. clinical pharmacological community to ensure the optimal growth of that field and obtain the resulting increases in safety for patients.”
We successfully persuaded the USCIS after our team’s diligent work on this case. And thanks to premium processing, the case was expedited, and our client achieved his EB-1A approval shortly. We thank him for letting us represent his EB-1A application and be a part of this success story.